Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more

Navid Gholampour

Navid has over a decade of experience in Life Sciences recruitment. He partners with leaders to build patient-focused and innovative organisation

Navid Gholampour​